Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MK-0482 |
| Trade Name | |
| Synonyms | MK 0482|MK0482 |
| Drug Descriptions |
MK-0482 binds to ILT3 and prevents binding of ILT-3 ligands, leading to inhibition of ILT-3 dependent signaling, which may lead to increased antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2046), NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C180610 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Carboplatin + MK-0482 + Paclitaxel + Pembrolizumab | Carboplatin MK-0482 Paclitaxel Pembrolizumab | 0 | 1 |
| Carboplatin + MK-0482 + Pembrolizumab + Pemetrexed Disodium | Carboplatin MK-0482 Pembrolizumab Pemetrexed Disodium | 0 | 1 |
| MK-0482 | MK-0482 | 0 | 2 |
| MK-0482 + Pembrolizumab | MK-0482 Pembrolizumab | 0 | 2 |